Loading...

David Braff

Title(s)Recall Faculty, Psychiatry
SchoolHealth Sciences
Address9500 Gilman Drive #0804
La Jolla CA 92093
Phone619-543-5570
vCardDownload vCard

    Collapse Overview 
    Collapse Overview

    Biography

    David Braff, M.D. is Distinguished Professor of Psychiatry, and Director of the Schizophrenia Program at the University of California, San Diego, School of Medicine. He is also Director of the NIH-funded Consortium on the Genetics of Schizophrenia (COGS). He trained at the University of Pennsylvania, Yale University, and the University of California, San Francisco.

    Research Interests

    David Braff, M.D. is Distinguished Professor of Psychiatry, and Director of the Schizophrenia Program at the Department of Psychiatry, University of California San Diego School of Medicine. He is also Director and Lead Scientist of the NIH-funded multi-site Consortium on the Genetics of Schizophrenia (COGS). He trained at the University of Pennsylvania, Yale University, and the University of California, San Francisco.

    David Braff’s research interests have received long-term NIMH and NARSAD Distinguished Investigator funding and a special NIMH MERIT Award to extend his research as well as funding from the Veterans Administration. His interests center around 1) the identification of neurocognitive and neurophysiological biomarker deficits in psychiatric disorders (with an emphasis on schizophrenia); 2) understanding the neural circuit/substrate dysfunctions of schizophrenia patients using human and cross-species translational animal model studies; 3) using neurocognitive, imaging, information processing, and attentional dysregulation as endophenotypes in family/genetic studies; 4) utilizing translational and genetic research tools to identify the neural circuit basis and the genetic architecture of neuropsychiatric disorders such as schizophrenia; and 5) utilizing genetically and behaviorally determined, strong inference-based targets for developing efficacious antipsychotic medications and psychosocial therapies that can improve the functional outcome and quality of life of schizophrenia patients and reduce the devastating disease burden placed on them and their families by this “no fault” clinical brain disorder.

    David Braff has published over 250 articles and 300 reviews, book chapters and abstracts. He has received special recognition from the Institute for Scientific Information (ISI) as being in the top half of 1% of most highly cited neuropsychiatric researchers. In addition, he has been the Attending Physician for over 10,000 patients with schizophrenia and other serious mental disorders, and has trained many researchers and clinicians. Dr. Braff has served as Councilor, Executive Secretary and President of the Society of Biological Psychiatry (SOBP), and as a Councilor and President of the American College of Neuropsychopharmacology (ACNP), 2 world leading neuropsychiatric research societies. He has consulted to the Diagnostic and Statistical Manual (DSM IV and V) Committee of the APA, and Expert Treatment Committee of the American Psychiatric Association (APA). He is the Co-Chair of the Executive Committee and Director of the Clinical Neurosciences and Genomic Unit at the Veterans Administration VISN 22 Mental Illness, Research and Clinical Center (MIRECC) program in the Southwest United States which investigates psychosis and its treatment. He has also been a key figure in advancing the Mission of the International Congress on Schizophrenia Research (ICOSR) and liaisoned USA-Russia and USA-China cultural and grant cooperative projects. He served for 15 years as President of the campus-wide UCSD Faculty Association.

    David Braff has received numerous Grants, Awards, and Prizes. A Fellow of the American Psychiatric Association (APA), Dr. Braff received the Kempf Research Prize and Marmor Award for excellence in biopsychosocial research from the APA, as well as the Gold Medal for lifetime research accomplishments from the SOBP, and the Warren Award for schizophrenia research from the ICOSR. He received the George Thompson Award from the SOBP for service to the field, the Dean Award for Schizophrenia Research Excellence from the American College of Psychiatrists (ACP) as well as Gold Medal for psychiatric research from Society of Biological Psychiatry with other awards. He has been selected by his peers as one of the “Best Doctors” in the United States and in San Diego. He serves on many national and international committees and societies, such as the Executive Committee of the MATRICS Project of the NIMH, which identified novel cognitive targets for antipsychotic medications, and other NIMH advisory committees that focus on issues such as the design and conduct of large clinical treatment trials. Dr. Braff is on the Editorial Boards of the Archives of General Psychiatry and five other journals and reviews manuscripts for over 20 Top Journals. He has lectured nationally and internationally on many topics in neuropsychiatric science and practice, and is recognized as a leader of the international neuropsychiatric community.

    Collapse Research 
    Collapse Research Activities and Funding
    2/5-Gentics of Transcriptional Endophenotypes for Schizophrenia
    NIH/NIMH R01MH093533Apr 15, 2012 - Mar 31, 2015
    Role: Principal Investigator
    5/5:Family-Based Genome-Wide Methylation Scan in Neurocognition and Schizophrenia
    NIH/NIMH RC2MH089984Sep 30, 2009 - Aug 31, 2011
    Role: Principal Investigator
    4/4-A Genomic Approach to Schizophrenia
    NIH/NIMH R01MH084071Apr 16, 2009 - Jan 31, 2014
    Role: Principal Investigator
    5/5: A Genome-wide Methylation Scan for Epigenetic Contributions to Schizophrenia
    NIH/NIMH U01MH085265Sep 30, 2008 - May 31, 2014
    Role: Principal Investigator
    1/6-The Genetics of Endophenotypes and Schizophrenia
    NIH/NIMH R01MH065571Apr 4, 2003 - Jul 31, 2009
    Role: Principal Investigator
    General Clinical Research Center
    NIH/NCRR M01RR000827Jan 27, 1997 - Nov 30, 2010
    Role: Co-Investigator
    Gating and Inhibiting in Schizophrenia
    NIH/NIMH R01MH042228Jan 1, 1987 - Mar 31, 2008
    Role: Principal Investigator
    SENSORY GATING AND HABITUATION IN SCHIZOPHRENIA
    NIH/NIMH R37MH042228Jan 1, 1987 - Jan 31, 2003
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. The effects of age and sex on cognitive impairment in schizophrenia: Findings from the Consortium on the Genetics of Schizophrenia (COGS) study. PLoS One. 2020; 15(5):e0232855. Lee J, Green MF, Nuechterlein KH, Swerdlow NR, Greenwood TA, Hellemann GS, Lazzeroni LC, Light GA, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Sprock J, Stone WS, Sugar CA, Tsuang DW, Tsuang MT, Turetsky BI, Gur RC, Gur RE, Braff DL. PMID: 32401791.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    2. Genome-wide association study of cognitive performance in U.S. veterans with schizophrenia or bipolar disorder. Am J Med Genet B Neuropsychiatr Genet. 2020 Apr; 183(3):181-194. Harvey PD, Sun N, Bigdeli TB, Fanous AH, Aslan M, Malhotra AK, Lu Q, Hu Y, Li B, Chen Q, Mane S, Miller P, Rajeevan N, Sayward F, Cheung KH, Li Y, Greenwood TA, Gur RE, Braff DL, Brophy M, Pyarajan S, O'Leary TJ, Gleason T, Przygodszki R, Muralidhar S, Gaziano JM, Concato J, Zhao H, Siever LJ. PMID: 31872970.
      View in: PubMed   Mentions:    Fields:    
    3. Genome-wide Association of Endophenotypes for Schizophrenia From the Consortium on the Genetics of Schizophrenia (COGS) Study. JAMA Psychiatry. 2019 Oct 09. Greenwood TA, Lazzeroni LC, Maihofer AX, Swerdlow NR, Calkins ME, Freedman R, Green MF, Light GA, Nievergelt CM, Nuechterlein KH, Radant AD, Siever LJ, Silverman JM, Stone WS, Sugar CA, Tsuang DW, Tsuang MT, Turetsky BI, Gur RC, Gur RE, Braff DL. PMID: 31596458.
      View in: PubMed   Mentions:    Fields:    
    4. Contributions of common genetic variants to risk of schizophrenia among individuals of African and Latino ancestry. Mol Psychiatry. 2019 Oct 07. Bigdeli TB, Genovese G, Georgakopoulos P, Meyers JL, Peterson RE, Iyegbe CO, Medeiros H, Valderrama J, Achtyes ED, Kotov R, Stahl EA, Abbott C, Azevedo MH, Belliveau RA, Bevilacqua E, Bromet EJ, Byerley W, Carvalho CB, Chapman SB, DeLisi LE, Dumont AL, O'Dushlaine C, Evgrafov OV, Fochtmann LJ, Gage D, Kennedy JL, Kinkead B, Macedo A, Moran JL, Morley CP, Dewan MJ, Nemesh J, Perkins DO, Purcell SM, Rakofsky JJ, Scolnick EM, Sklar BM, Sklar P, Smoller JW, Sullivan PF, Macciardi F, Marder SR, Gur RC, Gur RE, Braff DL, Nicolini H, Escamilla MA, Vawter MP, Sobell JL, Malaspina D, Lehrer DS, Buckley PF, Rapaport MH, Knowles JA, Fanous AH, Pato MT, McCarroll SA, Pato CN. PMID: 31591465.
      View in: PubMed   Mentions: 2     Fields:    
    5. Lewis Judd, M.D. Neuropsychopharmacology. 2019 05; 44(6):1175. Grant I, Braff D. PMID: 30846851.
      View in: PubMed   Mentions:    Fields:    
    6. Nonlinear dynamics underlying sensory processing dysfunction in schizophrenia. Proc Natl Acad Sci U S A. 2019 02 26; 116(9):3847-3852. Lainscsek C, Sampson AL, Kim R, Thomas ML, Man K, Lainscsek X, Swerdlow NR, Braff DL, Sejnowski TJ, Light GA. PMID: 30808768.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    7. Targeted cognitive training improves auditory and verbal outcomes among treatment refractory schizophrenia patients mandated to residential care. Schizophr Res. 2018 12; 202:378-384. Thomas ML, Bismark AW, Joshi YB, Tarasenko M, Treichler EBH, Hochberger WC, Zhang W, Nungaray J, Sprock J, Cardoso L, Tiernan K, Attarha M, Braff DL, Vinogradov S, Swerdlow N, Light GA. PMID: 30055883.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    8. Deficient prepulse inhibition in schizophrenia in a multi-site cohort: Internal replication and extension. Schizophr Res. 2018 08; 198:6-15. Swerdlow NR, Light GA, Thomas ML, Sprock J, Calkins ME, Green MF, Greenwood TA, Gur RE, Gur RC, Lazzeroni LC, Nuechterlein KH, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Sugar CA, Tsuang DW, Tsuang MT, Turetsky BI, Braff DL. PMID: 28549722.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    9. Mismatch Negativity is a Sensitive and Predictive Biomarker of Perceptual Learning During Auditory Cognitive Training in Schizophrenia. Neuropsychopharmacology. 2017 Oct; 42(11):2206-2213. Perez VB, Tarasenko M, Miyakoshi M, Pianka ST, Makeig SD, Braff DL, Swerdlow NR, Light GA. PMID: 28139679.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    10. Modeling Deficits From Early Auditory Information Processing to Psychosocial Functioning in Schizophrenia. JAMA Psychiatry. 2017 Jan 01; 74(1):37-46. Thomas ML, Green MF, Hellemann G, Sugar CA, Tarasenko M, Calkins ME, Greenwood TA, Gur RE, Gur RC, Lazzeroni LC, Nuechterlein KH, Radant AD, Seidman LJ, Shiluk AL, Siever LJ, Silverman JM, Sprock J, Stone WS, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Braff DL, Light GA. PMID: 27926742.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    11. Endophenotypes, Epigenetics, Polygenicity and More: Irv Gottesman's Dynamic Legacy. Schizophr Bull. 2017 01; 43(1):10-16. Braff DL, Tamminga CA. PMID: 27872267.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    12. Sensorimotor gating of the startle reflex: what we said 25 years ago, what has happened since then, and what comes next. J Psychopharmacol. 2016 11; 30(11):1072-1081. Swerdlow NR, Braff DL, Geyer MA. PMID: 27539931.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansAnimals
    13. Constance E. Lieber, Theodore R. Stanley, and the Enduring Impact of Philanthropy on Psychiatry Research. Biol Psychiatry. 2016 07 15; 80(2):84-86. Krystal JH, Abi-Dargham A, Akbarian S, Arnsten AFT, Barch DM, Bearden CE, Braff DL, Brown ES, Bullmore ET, Carlezon WA, Carter CS, Cook EH, Daskalakis ZJ, DiLeone RJ, Duman RS, Grace AA, Hariri AR, Harrison PJ, Hiroi N, Kenny PJ, Kleinman JE, Krystal AD, Lewis DA, Lipska BK, Marder SR, Mason GF, Mathalon DH, McClung CA, McDougle CJ, McIntosh AM, McMahon FJ, Mirnics K, Monteggia LM, Narendran R, Nestler EJ, Neumeister A, O'Donovan MC, Öngür D, Pariante CM, Paulus MP, Pearlson G, Phillips ML, Pine DS, Pizzagalli DA, Pletnikov MV, Ragland JD, Rapoport JL, Ressler KJ, Russo SJ, Sanacora G, Sawa A, Schatzberg AF, Shaham Y, Shamay-Tsoory SG, Sklar P, State MW, Stein MB, Strakowski SM, Taylor SF, Turecki G, Turetsky BI, Weissman MM, Zachariou V, Zarate CA, Zubieta JK. PMID: 27346079.
      View in: PubMed   Mentions: 1     Fields:    
    14. Association of DNA Methylation Differences With Schizophrenia in an Epigenome-Wide Association Study. JAMA Psychiatry. 2016 05 01; 73(5):506-14. Montano C, Taub MA, Jaffe A, Briem E, Feinberg JI, Trygvadottir R, Idrizi A, Runarsson A, Berndsen B, Gur RC, Moore TM, Perry RT, Fugman D, Sabunciyan S, Yolken RH, Hyde TM, Kleinman JE, Sobell JL, Pato CN, Pato MT, Go RC, Nimgaonkar V, Weinberger DR, Braff D, Gur RE, Fallin MD, Feinberg AP. PMID: 27074206.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCells
    15. Prioritizing schizophrenia endophenotypes for future genetic studies: An example using data from the COGS-1 family study. Schizophr Res. 2016 07; 174(1-3):1-9. Millard SP, Shofer J, Braff D, Calkins M, Cadenhead K, Freedman R, Green MF, Greenwood TA, Gur R, Gur R, Lazzeroni LC, Light GA, Olincy A, Nuechterlein K, Seidman L, Siever L, Silverman J, Stone WS, Sprock J, Sugar CA, Swerdlow NR, Tsuang M, Turetsky B, Radant A, Tsuang DW. PMID: 27132484.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    16. Measuring the capacity for auditory system plasticity: An examination of performance gains during initial exposure to auditory-targeted cognitive training in schizophrenia. Schizophr Res. 2016 Apr; 172(1-3):123-30. Tarasenko M, Perez VB, Pianka ST, Vinogradov S, Braff DL, Swerdlow NR, Light GA. PMID: 26851143.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    17. Genetic assessment of additional endophenotypes from the Consortium on the Genetics of Schizophrenia Family Study. Schizophr Res. 2016 Jan; 170(1):30-40. Greenwood TA, Lazzeroni LC, Calkins ME, Freedman R, Green MF, Gur RE, Gur RC, Light GA, Nuechterlein KH, Olincy A, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Sugar CA, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Braff DL. PMID: 26597662.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    18. Gating Deficit Heritability and Correlation With Increased Clinical Severity in Schizophrenia Patients With Positive Family History. Am J Psychiatry. 2016 Apr 01; 173(4):385-91. Greenwood TA, Light GA, Swerdlow NR, Calkins ME, Green MF, Gur RE, Gur RC, Lazzeroni LC, Nuechterlein KH, Olincy A, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Sugar CA, Tsuang DW, Tsuang MT, Turetsky BI, Freedman R, Braff DL. PMID: 26441157.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    19. Erratum: The relationship between dopamine receptor D1 and cognitive performance. NPJ Schizophr. 2015; 1:15018. Tsang J, Fullard JF, Giakoumaki SG, Katsel P, Eirini Karagiorga V, Greenwood TA, Braff DL, Siever LJ, Bitsios P, Haroutunian V, Roussos P. PMID: 27336628.
      View in: PubMed   Mentions:
    20. Neurocognitive performance in family-based and case-control studies of schizophrenia. Schizophr Res. 2015 Apr; 163(1-3):17-23. Gur RC, Braff DL, Calkins ME, Dobie DJ, Freedman R, Green MF, Greenwood TA, Lazzeroni LC, Light GA, Nuechterlein KH, Olincy A, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Sprock J, Stone WS, Sugar CA, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Gur RE. PMID: 25432636.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    21. The importance of endophenotypes in schizophrenia research. Schizophr Res. 2015 Apr; 163(1-3):1-8. Braff DL. PMID: 25795083.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    22. Attention/vigilance in schizophrenia: performance results from a large multi-site study of the Consortium on the Genetics of Schizophrenia (COGS). Schizophr Res. 2015 Apr; 163(1-3):38-46. Nuechterlein KH, Green MF, Calkins ME, Greenwood TA, Gur RE, Gur RC, Lazzeroni LC, Light GA, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Sprock J, Stone WS, Sugar CA, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Braff DL. PMID: 25749017.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    23. The relationship between dopamine receptor D1 and cognitive performance. NPJ Schizophr. 2015; 1:14002. Tsang J, Fullard JF, Giakoumaki SG, Katsel P, Katsel P, Karagiorga VE, Greenwood TA, Braff DL, Siever LJ, Bitsios P, Haroutunian V, Roussos P. PMID: 27336024.
      View in: PubMed   Mentions:
    24. Factor structure and heritability of endophenotypes in schizophrenia: findings from the Consortium on the Genetics of Schizophrenia (COGS-1). Schizophr Res. 2015 Apr; 163(1-3):73-9. Seidman LJ, Hellemann G, Nuechterlein KH, Greenwood TA, Braff DL, Cadenhead KS, Calkins ME, Freedman R, Gur RE, Gur RC, Lazzeroni LC, Light GA, Olincy A, Radant AD, Siever LJ, Silverman JM, Sprock J, Stone WS, Sugar C, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Green MF. PMID: 25682549.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    25. Robust differences in antisaccade performance exist between COGS schizophrenia cases and controls regardless of recruitment strategies. Schizophr Res. 2015 Apr; 163(1-3):47-52. Radant AD, Millard SP, Braff DL, Calkins ME, Dobie DJ, Freedman R, Green MF, Greenwood TA, Gur RE, Gur RC, Lazzeroni LC, Light GA, Meichle SP, Nuechterlein KH, Olincy A, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow NR, Sugar CA, Tsuang MT, Turetsky BI, Tsuang DW. PMID: 25553977.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    26. California Verbal Learning Test-II performance in schizophrenia as a function of ascertainment strategy: comparing the first and second phases of the Consortium on the Genetics of Schizophrenia (COGS). Schizophr Res. 2015 Apr; 163(1-3):32-7. Stone WS, Mesholam-Gately RI, Braff DL, Calkins ME, Freedman R, Green MF, Greenwood TA, Gur RE, Gur RC, Lazzeroni LC, Light GA, Nuechterlein KH, Olincy A, Radant AD, Siever LJ, Silverman JM, Sprock J, Sugar CA, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Seidman LJ. PMID: 25497440.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    27. Enoch Callaway. Neuropsychopharmacology. 2014 Dec; 39(13):3125. Braff D. PMID: 25381704.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    28. Genomic substrates of neurophysiological endophenotypes: where we've been and where we're going. Psychophysiology. 2014 Dec; 51(12):1323-4. Braff DL. PMID: 25387712.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    29. Qualitative and quantitative aspects of information processing in first psychosis: latent class analyses in patients, at-risk subjects, and controls. Psychophysiology. 2015 Apr; 52(4):585-93. van Tricht MJ, Bour LJ, Koelman JH, Derks EM, Braff DL, de Wilde OM, Boerée T, Linszen DH, de Haan L, Nieman DH. PMID: 25376718.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    30. Consortium on the Genetics of Schizophrenia (COGS) assessment of endophenotypes for schizophrenia: an introduction to this Special Issue of Schizophrenia Research. Schizophr Res. 2015 Apr; 163(1-3):9-16. Swerdlow NR, Gur RE, Braff DL. PMID: 25454799.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    31. Validation of mismatch negativity and P3a for use in multi-site studies of schizophrenia: characterization of demographic, clinical, cognitive, and functional correlates in COGS-2. Schizophr Res. 2015 Apr; 163(1-3):63-72. Light GA, Swerdlow NR, Thomas ML, Calkins ME, Green MF, Greenwood TA, Gur RE, Gur RC, Lazzeroni LC, Nuechterlein KH, Pela M, Radant AD, Seidman LJ, Sharp RF, Siever LJ, Silverman JM, Sprock J, Stone WS, Sugar CA, Tsuang DW, Tsuang MT, Braff DL, Turetsky BI. PMID: 25449710.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    32. The auditory brain-stem response to complex sounds: a potential biomarker for guiding treatment of psychosis. Front Psychiatry. 2014; 5:142. Tarasenko MA, Swerdlow NR, Makeig S, Braff DL, Light GA. PMID: 25352811.
      View in: PubMed   Mentions:
    33. The utility of P300 as a schizophrenia endophenotype and predictive biomarker: clinical and socio-demographic modulators in COGS-2. Schizophr Res. 2015 Apr; 163(1-3):53-62. Turetsky BI, Dress EM, Braff DL, Calkins ME, Green MF, Greenwood TA, Gur RE, Gur RC, Lazzeroni LC, Nuechterlein KH, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Sprock J, Stone WS, Sugar CA, Swerdlow NR, Tsuang DW, Tsuang MT, Light G. PMID: 25306203.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    34. Cortical substrates and functional correlates of auditory deviance processing deficits in schizophrenia. Neuroimage Clin. 2014; 6:424-37. Rissling AJ, Miyakoshi M, Sugar CA, Braff DL, Makeig S, Light GA. PMID: 25379456.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    35. Verbal working memory in schizophrenia from the Consortium on the Genetics of Schizophrenia (COGS) study: the moderating role of smoking status and antipsychotic medications. Schizophr Res. 2015 Apr; 163(1-3):24-31. Lee J, Green MF, Calkins ME, Greenwood TA, Gur RE, Gur RC, Lazzeroni LC, Light GA, Nuechterlein KH, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Sprock J, Stone WS, Sugar CA, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Braff DL. PMID: 25248939.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    36. Comparison of the heritability of schizophrenia and endophenotypes in the COGS-1 family study. Schizophr Bull. 2014 Nov; 40(6):1404-11. Light G, Greenwood TA, Swerdlow NR, Calkins ME, Freedman R, Green MF, Gur RE, Gur RC, Lazzeroni LC, Nuechterlein KH, Olincy A, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Sprock J, Stone WS, Sugar CA, Tsuang DW, Tsuang MT, Turetsky BI, Braff DL. PMID: 24903414.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    37. Paternal age of schizophrenia probands and endophenotypic differences from unaffected siblings. Psychiatry Res. 2014 Sep 30; 219(1):67-71. Schmeidler J, Lazzeroni LC, Swerdlow NR, Ferreira RP, Braff DL, Calkins ME, Cadenhead KS, Freedman R, Green MF, Greenwood TA, Gur RE, Gur RC, Light GA, Olincy A, Nuechterlein KH, Radant AD, Seidman LJ, Siever LJ, Stone WS, Sprock J, Sugar CA, Tsuang DW, Tsuang MT, Turetsky BI, Silverman JM. PMID: 24913833.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    38. Is there an association between advanced paternal age and endophenotype deficit levels in schizophrenia? PLoS One. 2014; 9(2):e88379. Tsuang D, Esterberg M, Braff D, Calkins M, Cadenhead K, Dobie D, Freedman R, Green MF, Greenwood T, Gur R, Gur R, Horan W, Lazzeroni LC, Light GA, Millard SP, Olincy A, Nuechterlein K, Seidman L, Siever L, Silverman J, Stone W, Sprock J, Sugar C, Swerdlow N, Tsuang M, Turetsky B, Radant A. PMID: 24523888.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    39. Deficient prepulse inhibition in schizophrenia detected by the multi-site COGS. Schizophr Res. 2014 Feb; 152(2-3):503-12. Swerdlow NR, Light GA, Sprock J, Calkins ME, Green MF, Greenwood TA, Gur RE, Gur RC, Lazzeroni LC, Nuechterlein KH, Radant AD, Ray A, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Sugar CA, Tsuang DW, Tsuang MT, Turetsky BI, Braff DL. PMID: 24405980.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    40. Using biomarkers to inform diagnosis, guide treatments and track response to interventions in psychotic illnesses. Biomark Med. 2014; 8(1):9-14. Perez VB, Swerdlow NR, Braff DL, Näätänen R, Light GA. PMID: 24325220.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    41. The neuropsychiatric translational revolution: still very early and still very challenging. JAMA Psychiatry. 2013 Aug; 70(8):777-9. Braff L, Braff DL. PMID: 23739986.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimals
    42. Spatial and temporal mapping of de novo mutations in schizophrenia to a fetal prefrontal cortical network. Cell. 2013 Aug 01; 154(3):518-29. Gulsuner S, Walsh T, Watts AC, Lee MK, Thornton AM, Casadei S, Rippey C, Shahin H, Nimgaonkar VL, Go RC, Savage RM, Swerdlow NR, Gur RE, Braff DL, King MC, McClellan JM. PMID: 23911319.
      View in: PubMed   Mentions: 191     Fields:    Translation:HumansCells
    43. Lack of use in the literature from the last 20 years supports dropping traditional schizophrenia subtypes from DSM-5 and ICD-11. Schizophr Bull. 2013 Jul; 39(4):751-3. Braff DL, Ryan J, Rissling AJ, Carpenter WT. PMID: 23674819.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    44. Genome-wide linkage analyses of 12 endophenotypes for schizophrenia from the Consortium on the Genetics of Schizophrenia. Am J Psychiatry. 2013 May; 170(5):521-32. Greenwood TA, Swerdlow NR, Gur RE, Cadenhead KS, Calkins ME, Dobie DJ, Freedman R, Green MF, Gur RC, Lazzeroni LC, Nuechterlein KH, Olincy A, Radant AD, Ray A, Schork NJ, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Sugar CA, Tsuang DW, Tsuang MT, Turetsky BI, Light GA, Braff DL. PMID: 23511790.
      View in: PubMed   Mentions: 50     Fields:    Translation:Humans
    45. Demand and modality of directed attention modulate "pre-attentive" sensory processes in schizophrenia patients and nonpsychiatric controls. Schizophr Res. 2013 May; 146(1-3):326-35. Rissling AJ, Park SH, Young JW, Rissling MB, Sugar CA, Sprock J, Mathias DJ, Pela M, Sharp RF, Braff DL, Light GA. PMID: 23490760.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    46. Sex differences in familiality effects on neurocognitive performance in schizophrenia. Biol Psychiatry. 2013 May 15; 73(10):976-84. Calkins ME, Ray A, Gur RC, Freedman R, Green MF, Greenwood TA, Light GA, Nuechterlein KH, Olincy A, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Sugar C, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Braff DL, Lazzeroni LC, Gur RE. PMID: 23395246.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    47. Neural substrates of normal and impaired preattentive sensory discrimination in large cohorts of nonpsychiatric subjects and schizophrenia patients as indexed by MMN and P3a change detection responses. Neuroimage. 2013 Feb 01; 66:594-603. Takahashi H, Rissling AJ, Pascual-Marqui R, Kirihara K, Pela M, Sprock J, Braff DL, Light GA. PMID: 23085112.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    48. Characterization of neurophysiologic and neurocognitive biomarkers for use in genomic and clinical outcome studies of schizophrenia. PLoS One. 2012; 7(7):e39434. Light GA, Swerdlow NR, Rissling AJ, Radant A, Sugar CA, Sprock J, Pela M, Geyer MA, Braff DL. PMID: 22802938.
      View in: PubMed   Mentions: 56     Fields:    Translation:Humans
    49. Disentangling early sensory information processing deficits in schizophrenia. Clin Neurophysiol. 2012 Oct; 123(10):1942-9. Rissling AJ, Braff DL, Swerdlow NR, Hellemann G, Rassovsky Y, Sprock J, Pela M, Light GA. PMID: 22608970.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    50. Hierarchical organization of gamma and theta oscillatory dynamics in schizophrenia. Biol Psychiatry. 2012 May 15; 71(10):873-80. Kirihara K, Rissling AJ, Swerdlow NR, Braff DL, Light GA. PMID: 22361076.
      View in: PubMed   Mentions: 38     Fields:    Translation:Humans
    51. Association analysis of 94 candidate genes and schizophrenia-related endophenotypes. PLoS One. 2012; 7(1):e29630. Greenwood TA, Light GA, Swerdlow NR, Radant AD, Braff DL. PMID: 22253750.
      View in: PubMed   Mentions: 53     Fields:    Translation:HumansCells
    52. Analysis of 94 candidate genes and 12 endophenotypes for schizophrenia from the Consortium on the Genetics of Schizophrenia. Am J Psychiatry. 2011 Sep; 168(9):930-46. Greenwood TA, Lazzeroni LC, Murray SS, Cadenhead KS, Calkins ME, Dobie DJ, Green MF, Gur RE, Gur RC, Hardiman G, Kelsoe JR, Leonard S, Light GA, Nuechterlein KH, Olincy A, Radant AD, Schork NJ, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Freedman R, Braff DL. PMID: 21498463.
      View in: PubMed   Mentions: 110     Fields:    Translation:Humans
    53. Gating in schizophrenia: from genes to cognition (to real world function?). Biol Psychiatry. 2011 Mar 01; 69(5):395-6. Braff DL. PMID: 21316513.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    54. Group and site differences on the California Verbal Learning Test in persons with schizophrenia and their first-degree relatives: findings from the Consortium on the Genetics of Schizophrenia (COGS). Schizophr Res. 2011 May; 128(1-3):102-10. Stone WS, Giuliano AJ, Tsuang MT, Braff DL, Cadenhead KS, Calkins ME, Dobie DJ, Faraone SV, Freedman R, Green MF, Greenwood TA, Gur RE, Gur RC, Light GA, Mintz J, Nuechterlein KH, Olincy A, Radant AD, Roe AH, Schork NJ, Siever LJ, Silverman JM, Swerdlow NR, Thomas AR, Tsuang DW, Turetsky BI, Seidman LJ. PMID: 21288694.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    55. Neurophysiologic markers of abnormal brain activity in schizophrenia. Curr Psychiatry Rep. 2010 Dec; 12(6):572-8. Rissling AJ, Makeig S, Braff DL, Light GA. PMID: 20857348.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    56. Superior size-weight illusion performance in patients with schizophrenia: evidence for deficits in forward models. Schizophr Res. 2010 Aug; 121(1-3):101-6. Williams LE, Ramachandran VS, Hubbard EM, Braff DL, Light GA. PMID: 19931421.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    57. Electroencephalography (EEG) and event-related potentials (ERPs) with human participants. Curr Protoc Neurosci. 2010 Jul; Chapter 6:Unit 6.25.1-24. Light GA, Williams LE, Minow F, Sprock J, Rissling A, Sharp R, Swerdlow NR, Braff DL. PMID: 20578033.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    58. Reduced multisensory integration in patients with schizophrenia on a target detection task. Neuropsychologia. 2010 Aug; 48(10):3128-36. Williams LE, Light GA, Braff DL, Ramachandran VS. PMID: 20600181.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    59. Inhibition of the P50 cerebral evoked response to repeated auditory stimuli: results from the Consortium on Genetics of Schizophrenia. Schizophr Res. 2010 Jun; 119(1-3):175-82. Olincy A, Braff DL, Adler LE, Cadenhead KS, Calkins ME, Dobie DJ, Green MF, Greenwood TA, Gur RE, Gur RC, Light GA, Mintz J, Nuechterlein KH, Radant AD, Schork NJ, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Wagner BD, Freedman R. PMID: 20382002.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    60. Antisaccade performance in schizophrenia patients, their first-degree biological relatives, and community comparison subjects: data from the COGS study. Psychophysiology. 2010 Sep; 47(5):846-56. Radant AD, Dobie DJ, Calkins ME, Olincy A, Braff DL, Cadenhead KS, Freedman R, Green MF, Greenwood TA, Gur RE, Gur RC, Light GA, Meichle SP, Millard SP, Mintz J, Nuechterlein KH, Schork NJ, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow NR, Tsuang MT, Turetsky BI, Tsuang DW. PMID: 20374545.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    61. Prepulse inhibition of the startle reflex: a window on the brain in schizophrenia. Curr Top Behav Neurosci. 2010; 4:349-71. Braff DL. PMID: 21312406.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    62. The relationship between preattentive sensory processing deficits and age in schizophrenia patients. Clin Neurophysiol. 2009 Nov; 120(11):1949-1957. Kiang M, Braff DL, Sprock J, Light GA. PMID: 19786365.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    63. Proceedings and data from The Schizophrenia Summit: a critical appraisal to improve the management of Schizophrenia. J Clin Psychiatry. 2009; 70 Suppl 1:4-46. Nasrallah HA, Keshavan MS, Benes FM, Braff DL, Green AI, Gur RE, Kane JM, Perkins DO, Weiden PJ, Weinberger DR, Correll CU. PMID: 19292973.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    64. Abnormal auditory N100 amplitude: a heritable endophenotype in first-degree relatives of schizophrenia probands. Biol Psychiatry. 2008 Dec 15; 64(12):1051-9. Turetsky BI, Greenwood TA, Olincy A, Radant AD, Braff DL, Cadenhead KS, Dobie DJ, Freedman R, Green MF, Gur RE, Gur RC, Light GA, Mintz J, Nuechterlein KH, Schork NJ, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow NR, Tsuang DW, Tsuang MT, Calkins ME. PMID: 18701089.
      View in: PubMed   Mentions: 45     Fields:    Translation:Humans
    65. Clinically responsible genetic testing in neuropsychiatric patients: a bridge too far and too soon. Am J Psychiatry. 2008 Aug; 165(8):952-5. Braff DL, Freedman R. PMID: 18676598.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    66. Realistic expectations of prepulse inhibition in translational models for schizophrenia research. Psychopharmacology (Berl). 2008 Aug; 199(3):331-88. Swerdlow NR, Weber M, Qu Y, Light GA, Braff DL. PMID: 18568339.
      View in: PubMed   Mentions: 188     Fields:    Translation:HumansAnimals
    67. It is time to take a stand for medical research and against terrorism targeting medical scientists. Biol Psychiatry. 2008 Apr 15; 63(8):725-7. Krystal JH, Carter CS, Geschwind D, Manji HK, March JS, Nestler EJ, Zubieta JK, Charney DS, Goldman D, Gur RE, Lieberman JA, Roy-Byrne P, Rubinow DR, Anderson SA, Barondes S, Berman KF, Blair J, Braff DL, Brown ES, Calabrese JR, Carlezon WA, Cook EH, Davidson RJ, Davis M, Desimone R, Drevets WC, Duman RS, Essock SM, Faraone SV, Freedman R, Friston KJ, Gelernter J, Geller B, Gill M, Gould E, Grace AA, Grillon C, Gueorguieva R, Hariri AR, Innis RB, Jones EG, Kleinman JE, Koob GF, Krystal AD, Leibenluft E, Levinson DF, Levitt PR, Lewis DA, Liberzon I, Lipska BK, Marder SR, Markou A, Mason GF, McDougle CJ, McEwen BS, McMahon FJ, Meaney MJ, Meltzer HY, Merikangas KR, Meyer-Lindenberg A, Mirnics K, Monteggia LM, Neumeister A, O'Brien CP, Owen MJ, Pine DS, Rapoport JL, Rauch SL, Robbins TW, Rosenbaum JF, Rosenberg DR, Ross CA, Rush AJ, Sackeim HA, Sanacora G, Schatzberg AF, Shaham Y, Siever LJ, Sunderland T, Tecott LH, Thase ME, Todd RD, Weissman MM, Yehuda R, Yoshikawa T, Young EA, McCandless R. PMID: 18371494.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimals
    68. Verbal working memory impairments in individuals with schizophrenia and their first-degree relatives: findings from the Consortium on the Genetics of Schizophrenia. Schizophr Res. 2008 Aug; 103(1-3):218-28. Horan WP, Braff DL, Nuechterlein KH, Sugar CA, Cadenhead KS, Calkins ME, Dobie DJ, Freedman R, Greenwood TA, Gur RE, Gur RC, Light GA, Mintz J, Olincy A, Radant AD, Schork NJ, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Green MF. PMID: 18406578.
      View in: PubMed   Mentions: 43     Fields:    Translation:Humans
    69. Advances in endophenotyping schizophrenia. World Psychiatry. 2008 Feb; 7(1):11-8. Braff DL, Greenwood TA, Swerdlow NR, Light GA, Schork NJ. PMID: 18458787.
      View in: PubMed   Mentions:
    70. An event-related brain potential study of direct and indirect semantic priming in schizophrenia. Am J Psychiatry. 2008 Jan; 165(1):74-81. Kiang M, Kutas M, Light GA, Braff DL. PMID: 18056222.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    71. Initial heritability analyses of endophenotypic measures for schizophrenia: the consortium on the genetics of schizophrenia. Arch Gen Psychiatry. 2007 Nov; 64(11):1242-50. Greenwood TA, Braff DL, Light GA, Cadenhead KS, Calkins ME, Dobie DJ, Freedman R, Green MF, Gur RE, Gur RC, Mintz J, Nuechterlein KH, Olincy A, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Schork NJ. PMID: 17984393.
      View in: PubMed   Mentions: 153     Fields:    Translation:Humans
    72. Social Cognition and Neurocognition: Effects of Risperidone, Olanzapine, and Haloperidol. Am J Psychiatry. 2007 Oct 01; 164(10):1585-1592. Sergi M, Green M, Widmark C, Reist C, Erhart S, Braff D, Kee K, Marder S, Mintz J. PMID: 22688151.
      View in: PubMed   Mentions:    Fields:    
    73. Preattentive sensory processing as indexed by the MMN and P3a brain responses is associated with cognitive and psychosocial functioning in healthy adults. J Cogn Neurosci. 2007 Oct; 19(10):1624-32. Light GA, Swerdlow NR, Braff DL. PMID: 18271737.
      View in: PubMed   Mentions: 50     Fields:    Translation:Humans
    74. Social cognition [corrected] and neurocognition: effects of risperidone, olanzapine, and haloperidol. Am J Psychiatry. 2007 Oct; 164(10):1585-92. Sergi MJ, Green MF, Widmark C, Reist C, Erhart S, Braff DL, Kee KS, Marder SR, Mintz J. PMID: 17898351.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    75. Effects of olanzapine, risperidone and haloperidol on prepulse inhibition in schizophrenia patients: a double-blind, randomized controlled trial. Schizophr Res. 2007 Sep; 95(1-3):134-42. Wynn JK, Green MF, Sprock J, Light GA, Widmark C, Reist C, Erhart S, Marder SR, Mintz J, Braff DL. PMID: 17662577.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    76. Cognitive, neurophysiological, and functional correlates of proverb interpretation abnormalities in schizophrenia. J Int Neuropsychol Soc. 2007 Jul; 13(4):653-63. Kiang M, Light GA, Prugh J, Coulson S, Braff DL, Kutas M. PMID: 17521483.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    77. Endophenotyping schizophrenia. Am J Psychiatry. 2007 May; 164(5):705-7. Braff D, Schork NJ, Gottesman II. PMID: 17475726.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    78. Electrophysiological insights into conceptual disorganization in schizophrenia. Schizophr Res. 2007 May; 92(1-3):225-36. Kiang M, Kutas M, Light GA, Braff DL. PMID: 17383161.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    79. Multi-site studies of acoustic startle and prepulse inhibition in humans: initial experience and methodological considerations based on studies by the Consortium on the Genetics of Schizophrenia. Schizophr Res. 2007 May; 92(1-3):237-51. Swerdlow NR, Sprock J, Light GA, Cadenhead K, Calkins ME, Dobie DJ, Freedman R, Green MF, Greenwood TA, Gur RE, Mintz J, Olincy A, Nuechterlein KH, Radant AD, Schork NJ, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Tsuang DW, Tsuang MT, Turetsky BI, Braff DL. PMID: 17346930.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    80. Prepulse inhibition and P50 suppression are both deficient but not correlated in schizophrenia patients. Biol Psychiatry. 2007 May 15; 61(10):1204-7. Braff DL, Light GA, Swerdlow NR. PMID: 17161386.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    81. Social cognition in schizophrenia: relationships with neurocognition and negative symptoms. Schizophr Res. 2007 Feb; 90(1-3):316-24. Sergi MJ, Rassovsky Y, Widmark C, Reist C, Erhart S, Braff DL, Marder SR, Green MF. PMID: 17141477.
      View in: PubMed   Mentions: 82     Fields:    Translation:Humans
    82. Startle gating deficits in a large cohort of patients with schizophrenia: relationship to medications, symptoms, neurocognition, and level of function. Arch Gen Psychiatry. 2006 Dec; 63(12):1325-35. Swerdlow NR, Light GA, Cadenhead KS, Sprock J, Hsieh MH, Braff DL. PMID: 17146007.
      View in: PubMed   Mentions: 117     Fields:    Translation:Humans
    83. Deconstructing schizophrenia: an overview of the use of endophenotypes in order to understand a complex disorder. Schizophr Bull. 2007 Jan; 33(1):21-32. Braff DL, Freedman R, Schork NJ, Gottesman II. PMID: 17088422.
      View in: PubMed   Mentions: 128     Fields:    Translation:Humans
    84. The Consortium on the Genetics of Endophenotypes in Schizophrenia: model recruitment, assessment, and endophenotyping methods for a multisite collaboration. Schizophr Bull. 2007 Jan; 33(1):33-48. Calkins ME, Dobie DJ, Cadenhead KS, Olincy A, Freedman R, Green MF, Greenwood TA, Gur RE, Gur RC, Light GA, Mintz J, Nuechterlein KH, Radant AD, Schork NJ, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Braff DL. PMID: 17035358.
      View in: PubMed   Mentions: 65     Fields:    Translation:Humans
    85. Statistical genetics concepts and approaches in schizophrenia and related neuropsychiatric research. Schizophr Bull. 2007 Jan; 33(1):95-104. Schork NJ, Greenwood TA, Braff DL. PMID: 17035359.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    86. Successful multi-site measurement of antisaccade performance deficits in schizophrenia. Schizophr Res. 2007 Jan; 89(1-3):320-9. Radant AD, Dobie DJ, Calkins ME, Olincy A, Braff DL, Cadenhead KS, Freedman R, Green MF, Greenwood TA, Gur RE, Light GA, Meichle SP, Mintz J, Nuechterlein KH, Schork NJ, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow NR, Tsuang MT, Turetsky BI, Tsuang DW. PMID: 17023145.
      View in: PubMed   Mentions: 35     Fields:    Translation:Humans
    87. The neural correlates of habituation of response to startling tactile stimuli presented in a functional magnetic resonance imaging environment. Psychiatry Res. 2006 Nov 22; 148(1):1-10. McDowell JE, Brown GG, Lazar N, Camchong J, Sharp R, Krebs-Thomson K, Eyler LT, Braff DL, Geyer MA. PMID: 17000088.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    88. Gamma band oscillations reveal neural network cortical coherence dysfunction in schizophrenia patients. Biol Psychiatry. 2006 Dec 01; 60(11):1231-40. Light GA, Hsu JL, Hsieh MH, Meyer-Gomes K, Sprock J, Swerdlow NR, Braff DL. PMID: 16893524.
      View in: PubMed   Mentions: 133     Fields:    Translation:Humans
    89. Convergence and divergence in the neurochemical regulation of prepulse inhibition of startle and N40 suppression in rats. Neuropsychopharmacology. 2006 Mar; 31(3):506-15. Swerdlow NR, Geyer MA, Shoemaker JM, Light GA, Braff DL, Stevens KE, Sharp R, Breier M, Neary A, Auerbach PP. PMID: 16123772.
      View in: PubMed   Mentions: 15     Fields:    Translation:Animals
    90. Prepulse-elicited motor reactions do not differ between schizophrenia patients and control subjects. Behav Neurosci. 2006 Feb; 120(1):224-7. Swerdlow NR, Sprock J, Braff DL. PMID: 16492135.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    91. Effects of background and prepulse characteristics on prepulse inhibition and facilitation: implications for neuropsychiatric research. Biol Psychiatry. 2006 Mar 15; 59(6):555-9. Hsieh MH, Swerdlow NR, Braff DL. PMID: 16169529.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    92. Stability of mismatch negativity deficits and their relationship to functional impairments in chronic schizophrenia. Am J Psychiatry. 2005 Sep; 162(9):1741-3. Light GA, Braff DL. PMID: 16135637.
      View in: PubMed   Mentions: 63     Fields:    Translation:Humans
    93. P50 suppression in individuals at risk for schizophrenia: the convergence of clinical, familial, and vulnerability marker risk assessment. Biol Psychiatry. 2005 Jun 15; 57(12):1504-9. Cadenhead KS, Light GA, Shafer KM, Braff DL. PMID: 15953486.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    94. On the waveform of the acoustic startle blink in the paradigm of prepulse inhibition - methodological and physiological aspects. Neuropsychobiology. 2005; 52(1):24-7. Meincke U, Light GA, Geyer MA, Braff DL. PMID: 15942260.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    95. Prepulse inhibition of perceived stimulus intensity: paradigm assessment. Biol Psychol. 2005 May; 69(2):133-47. Swerdlow NR, Stephany NL, Talledo J, Light G, Braff DL, Baeyens D, Auerbach PP. PMID: 15804542.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    96. Female schizophrenia patients have prepulse inhibition deficits. Biol Psychiatry. 2005 Apr 01; 57(7):817-20. Braff DL, Light GA, Ellwanger J, Sprock J, Swerdlow NR. PMID: 15820241.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    97. Startle modulation in Caucasian-Americans and Asian-Americans: a prelude to genetic/endophenotypic studies across the 'Pacific Rim'. Psychiatr Genet. 2005 Mar; 15(1):61-5. Swerdlow NR, Talledo JA, Braff DL. PMID: 15722959.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    98. Mismatch negativity deficits are associated with poor functioning in schizophrenia patients. Arch Gen Psychiatry. 2005 Feb; 62(2):127-36. Light GA, Braff DL. PMID: 15699289.
      View in: PubMed   Mentions: 113     Fields:    Translation:Humans
    99. The use of neurophysiological endophenotypes to understand the genetic basis of schizophrenia. Dialogues Clin Neurosci. 2005; 7(2):125-35. Braff DL, Light GA. PMID: 16262208.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansAnimals
    100. Preattentional and attentional cognitive deficits as targets for treating schizophrenia. Psychopharmacology (Berl). 2004 Jun; 174(1):75-85. Braff DL, Light GA. PMID: 15118804.
      View in: PubMed   Mentions: 63     Fields:    Translation:HumansAnimals
    101. Sensitization and habituation of the acoustic startle reflex in patients with schizophrenia. Psychiatry Res. 2004 Apr 15; 126(1):51-61. Meincke U, Light GA, Geyer MA, Braff DL, Gouzoulis-Mayfrank E. PMID: 15081627.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    102. The value of referring to recently introduced antipsychotics as "second generation". Am J Psychiatry. 2003 Aug; 160(8):1371-2. Lohr JB, Braff DL. PMID: 12900294.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    103. Visual masking as a probe for abnormal gamma range activity in schizophrenia. Biol Psychiatry. 2003 Jun 15; 53(12):1113-9. Green MF, Mintz J, Salveson D, Nuechterlein KH, Breitmeyer B, Light GA, Braff DL. PMID: 12814862.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    104. The relationship of age to prepulse inhibition and habituation of the acoustic startle response. Biol Psychol. 2003 Mar; 62(3):175-95. Ellwanger J, Geyer MA, Braff DL. PMID: 12633977.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    105. Some possible genetic parallels across alcoholism, bipolar disorder and schizophrenia. J Stud Alcohol. 2003 Mar; 64(2):157-9. Schuckit MA, Kelsoe JR, Braff DL, Wilhelmsen KC. PMID: 12713187.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    106. The use of the Ego Impairment Index across the schizophrenia spectrum. J Pers Assess. 2003 Feb; 80(1):50-7. Perry W, Minassian A, Cadenhead K, Sprock J, Braff D. PMID: 12584067.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    107. Chaos and schizophrenia: does the method fit the madness? Biol Psychiatry. 2003 Jan 01; 53(1):3-11. Paulus MP, Braff DL. PMID: 12513940.
      View in: PubMed   Mentions: 13     Fields:    
    108. Schizophrenia subjects show intact success-related neural activation but impaired uncertainty processing during decision-making. Neuropsychopharmacology. 2003 Apr; 28(4):795-806. Paulus MP, Frank L, Brown GG, Braff DL. PMID: 12655327.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    109. Information processing deficits in acutely psychotic schizophrenia patients medicated and unmedicated at the time of admission. Am J Psychiatry. 2002 Aug; 159(8):1375-81. Perry W, Feifel D, Minassian A, Bhattacharjie I, Braff DL. PMID: 12153831.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    110. Parietal dysfunction is associated with increased outcome-related decision-making in schizophrenia patients. Biol Psychiatry. 2002 Jun 15; 51(12):995-1004. Paulus MP, Hozack NE, Zauscher BE, Frank L, Brown GG, McDowell J, Braff DL. PMID: 12062884.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    111. Neurobiological measures of schizotypal personality disorder: defining an inhibitory endophenotype? Am J Psychiatry. 2002 May; 159(5):869-71. Cadenhead KS, Light GA, Geyer MA, McDowell JE, Braff DL. PMID: 11986147.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    112. Endophenotyping schizotypy: a prelude to genetic studies within the schizophrenia spectrum. Schizophr Res. 2002 Mar 01; 54(1-2):47-57. Cadenhead KS, Braff DL. PMID: 11853978.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    113. Neural correlates of refixation saccades and antisaccades in normal and schizophrenia subjects. Biol Psychiatry. 2002 Feb 01; 51(3):216-23. McDowell JE, Brown GG, Paulus M, Martinez A, Stewart SE, Dubowitz DJ, Braff DL. PMID: 11839364.
      View in: PubMed   Mentions: 47     Fields:    Translation:Humans
    114. Behavioral and functional neuroimaging evidence for prefrontal dysfunction in methamphetamine-dependent subjects. Neuropsychopharmacology. 2002 Jan; 26(1):53-63. Paulus MP, Hozack NE, Zauscher BE, Frank L, Brown GG, Braff DL, Schuckit MA. PMID: 11751032.
      View in: PubMed   Mentions: 99     Fields:    Translation:HumansCTClinical Trials
    115. Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl). 2001 Jul; 156(2-3):234-58. Braff DL, Geyer MA, Swerdlow NR. PMID: 11549226.
      View in: PubMed   Mentions: 498     Fields:    Translation:Humans
    116. Impact of prepulse characteristics on the detection of sensorimotor gating deficits in schizophrenia. Schizophr Res. 2001 Apr 15; 49(1-2):171-8. Braff DL, Geyer MA, Light GA, Sprock J, Perry W, Cadenhead KS, Swerdlow NR. PMID: 11343875.
      View in: PubMed   Mentions: 90     Fields:    Translation:Humans
    117. Symptom correlates of prepulse inhibition deficits in male schizophrenic patients. Am J Psychiatry. 1999 Apr; 156(4):596-602. Braff DL, Swerdlow NR, Geyer MA. PMID: 10200740.
      View in: PubMed   Mentions: 68     Fields:    Translation:Humans
    118. Hemispheric and attentional contributions to perceptual organization deficits on the global-local task in schizophrenia. Neuropsychology. 1999 Apr; 13(2):271-281. Granholm E, Perry W, Filoteo JV, Braff D. PMID: 10353376.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    David's Networks
    Concepts (321)
    Derived automatically from this person's publications.
    _
    Co-Authors (50)
    People in Profiles who have published with this person.
    _
    Similar People (55)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _